# Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Source: https://onco.cc/trials/nct06413745/  
OnCo record `nct06413745` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab rezetecan in biliary tract cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT06413745 by Jiangsu HengRui Medicine Co., Ltd., with 59 participants enrolled, started 2024-06-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: SHR-A1811.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06413745
- Phase: 2
- Setting: A Phase II Clinical Study of SHR-A1811 in Patients With HER2-expressing/Amplified, Locally Advanced, Unresectable or Metastatic Biliary Tract Cancer (BTC) Who Have Previously Failed First or Second-line Systemic Therapy
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 59

## Sources

- ClinicalTrials.gov NCT06413745: https://clinicaltrials.gov/study/NCT06413745

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06413745.json